Biofrontera AG
Deutsche BörseTotal Valuation
Biofrontera AG carries a market capitalization of 13.98M, placing it among publicly traded companies globally. Its enterprise value stands at 10.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.98M |
| Enterprise Value | 10.54M |
Share Statistics
Biofrontera AG currently has 6.08M shares outstanding.
| Shares Outstanding | 6.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.70, and the price-to-book ratio stands at -0.13.
| PE Ratio | N/A |
| PS Ratio | 0.70 |
| PB Ratio | -0.13 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.50 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2,988.70 |
Financial Position
Biofrontera AG maintains a current ratio of 1.76, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.33, indicating elevated leverage, while an interest coverage ratio of -617.62 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.76 |
| Quick Ratio | 0.57 |
| Debt / Equity | 3.33 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -617.62 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -3.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.80 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.92 |
Taxes
| Income Tax | -2.37M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Biofrontera AG's stock has declined approximately -7.25806% over the past 52 weeks. The 50-day moving average sits at 2.44, while the 200-day moving average is 2.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.25806% |
| 50-Day Moving Average | 2.44 |
| 200-Day Moving Average | 2.56 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Biofrontera AG generated 21.23M in revenue and converted that into -965,000.00 in net income, yielding earnings per share of -0.30. EBITDA reached -4.94M, while operating income came in at -4.94M.
| Revenue | 21.23M |
| Gross Profit | 16.54M |
| Operating Income | -4.94M |
| Pretax Income | -4.24M |
| Net Income | -965,000.00 |
| EBITDA | -4.94M |
| EBIT | -4.94M |
| Earnings Per Share (EPS) | -0.30 |
Balance Sheet
Biofrontera AG holds 4.95M in cash and equivalents against 651,000.00 in total debt, resulting in a net debt position of -4.25M. Total book value stands at -117.98M, with working capital of 6.66M providing operational flexibility.
| Cash & Cash Equivalents | 4.95M |
| Total Debt | 651,000.00 |
| Net Debt | -4.25M |
| Equity (Book Value) | -117.98M |
| Book Value Per Share | -19.08 |
| Working Capital | 6.66M |
Margins
Biofrontera AG operates with a gross margin of 77.90, reflecting its pricing power and cost economics. The operating margin of -23.28 and net profit margin of -4.55 provide insight into operational efficiency.
| Gross Margin | 77.90 |
| Operating Margin | -23.28 |
| Pretax Margin | -19.97 |
| Profit Margin | -4.55 |
| EBITDA Margin | -23.28 |
Stock Splits
Biofrontera AG's most recent stock split took place on May 14, 2024 with a 21:1 split ratio.
| Last Split Date | 5/14/2024 |
| Split Ratio | 21:1 |
Scores
Biofrontera AG posts an Altman Z-Score of -4.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.84 |